Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antioxidant Selenium Offers No Heart-Disease Protection

26.04.2006


Selenium does not protect against cardiovascular disease, despite its documented antioxidant and chemopreventive properties, analysis of a randomized placebo-controlled clinical trial covering 13 years has shown.



The selenium-CVD association was a secondary endpoint in the Nutritional Prevention of Cancer Trial, which was designed primarily to determine if selenium supplementation could prevent the recurrence of non-melanoma skin cancer.

Results of the trial, the only large randomized clinical trial to date to examine selenium supplementation alone in the prevention of CVD, appear in the April 15 issue of the American Journal of Epidemiology. Saverio Stranges, M.D., Ph.D., assistant professor of social and preventive medicine in the School of Public Health and Health Professions, University at Buffalo, is first author.


"Our results extend previous research based on smaller intervention trials focusing on cardiovascular risk factors," said Stranges. "Our findings are consistent with those from previous studies that have shown no beneficial effect of selenium supplementation in combination with other antioxidants on the primary prevention of cardiovascular disease."

Several antioxidants, vitamins C and E in particular, that were thought to play a role in preventing heart disease based on observational studies have turned out not to be protective in randomized clinical trials, and selenium now has joined this group.

The main findings of this report focus on the 1,004 participants in the study, conducted from 1983-96, who were free of cardiovascular disease when they were recruited. Participants came from seven dermatology clinics in low selenium areas of the eastern United States: Augusta and Macon, Ga.; Columbia, S.C.; Miami, Fla.; Wilson and Greenville, N. C.; and Newington, Conn.

Enrollees were assigned randomly to take a tablet containing 200 micrograms of selenium daily or a placebo. Information on sociodemographics, health habits, education and body mass index also was collected.

Participants provided blood samples at their respective clinics twice a year and reported any new illnesses or medications. Individuals were followed for an average of 7.6 years.

Results showed no association between selenium supplementation on any of the endpoints studied: coronary heart disease, stroke or deaths from cardiovascular disease, Stranges said. There also was no difference in the endpoints based on the level of selenium at baseline. In addition, the lack of significant association with CVD endpoints was confirmed even in the 246 participants who had CVD at baseline. (This data does not appear in the published manuscript.)

"These results must be interpreted cautiously," said Stranges, "because they result from exploratory analyses, although from the largest randomized clinical trial available that has selenium only as the intervention. However, this report adds important information to our knowledge on the role of selenium in cardiovascular-disease prevention, indicating no overall benefit of supplementation by selenium alone in prevention of cardiovascular disease."

Additional contributors to the study were James R. Marshal, Ph.D., Raj Natarajan and Mary E. Reid, Ph.D., from Roswell Park Cancer Institute in Buffalo; Maurizio Trevisan, M.D., and Richard P. Donahue, M.P.H., Ph.D., of the UB School of Public Health and Health Professions; Gerald F. Combs, Jr., Ph.D., from the USDA Human Nutrition Research Center in Grand Forks, N.D.; Eduardo Farinaro, M.D., of "Federico II" University of Naples Medical School, Naples, Italy, and the late Larry C. Clark, M.P.H., Ph.D., a major contributor to research on selenium and prostate cancer.

The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York.

Lois Baker | EurekAlert!
Further information:
http://www.buffalo.edu

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>